Radiopharm Theranostics to Present RAD101 Data at SNO26 Annual Meeting

Radiopharm Theranostics selected for a late-breaking oral presentation of positive data from an interim analysis of its U.S. Phase 2b imaging trial of RAD101 at the 2026 Society of Neuro-Oncology Annual Meeting. RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint. A meeting with the FDA is planned on October 1st to align on RAD101 Phase 3 pivotal trial protocol. The brain metastases imaging market has a total addressable market of ~$600 million, and there are no currently approved PET products.